The seek of neuroprotection: Introducing cannabinoids

Recent Patents on CNS Drug Discovery

Volumn 2, Issue 2, 2007, Pages 131-139

  Martínez Orgado, Jose ^a   Fernández López, David ^b   Lizasoain, Ignacio ^b   Romero, Julián ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Brain; Cannabinoids; Hypoxia ischemia; Neuroprotection

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; AMINOALKYLINDOL DERIVATIVE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; DEXANABINOL; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; GW 1000; INDUCIBLE NITRIC OXIDE SYNTHASE; MEMBRANE PROTEIN; NITRIC OXIDE; PRS 211; RESORCINOL DERIVATIVE; RIMONABANT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; VANILLOID RECEPTOR;

ANTIOXIDANT ACTIVITY; APPETITE; ARTICLE; BODY MOVEMENT; BRAIN HYPOXIA; BRAIN INFARCTION; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM; CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; DRUG SYNTHESIS; FOREBRAIN; GLIA CELL; HUMAN; IMMUNOMODULATION; MEMORY; MOLECULAR CLONING; MOTIVATION; MULTIPLE SCLEROSIS; NERVE CELL; NERVE CELL NECROSIS; NEUROPATHIC PAIN; NEUROPROTECTION; NOCICEPTION; NONHUMAN; OXIDATIVE STRESS; PATENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SLEEP DISORDER; SPASTICITY; SYNAPTIC TRANSMISSION; THERMOREGULATION; VASODILATATION;

ANIMALS; BRAIN; CANNABINOIDS; HUMANS; HYPOXIA-ISCHEMIA, BRAIN; NEUROPROTECTIVE AGENTS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2;

EID: 34250692547     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488907780832724     Document Type: Article

References (135)

1. Mechoulam R, Lichtman AH. Stout guards of the central nervous system. Science 2003; 302(5642):65-67.
2. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003; 83(3):1017-1066.
3. Howlett AC, Breivogel C, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004; 47:345-358.
4. Duran M, Laptook AR, Capellà D. Novedades sobre las potencialidades terapéutiucas del Cannabis y el sistema cannabinoide. Med Clin (Barc) 2007; 122:390-398.
5. Baker D, Pryce G, Giuffrida A, Thompson A. The therapeutical potential of cannabis. Lancet Neurol 2003; 2:291-298.
6. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86:1646-1647.
7. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346(6284):561-564.
8. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002; 54(2):161-202.
9. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365(6441):61-65.
10. Stella N. Cannabinoid signaling in glial oells. Glia 2004; 48(4):267-277.
11. Romero J, Lastres-Becker I, De Miguel R, Berrendero F, Ramos JA, Fernandez-Ruiz J. The endogenous cannabinoid system and the basal ganglia, biochemical, pharmacological, and therapeutic aspects. Pharmacol Ther 2002; 95(2):137-152.
12. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258(5090):1946-1949.
13. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215(1):89-97.
14. Begg M, Pacher P, Batkai S, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106:133-145.
15. Pazos MR, Nunez E, Benito C, Tolon RM, Romero J. Functional neuroanatomy of the endocannabinoid system. Pharmacol Biochem Behav 2005; 81(2):239-247.
16. Maresz K, Carrier EJ, Ponomarev ED, Hillard CJ, Dittel BN. Modulation of the cannabinoid CB receptor in microglial cells in response to inflammatory stimuli. J Neurochem 2005; 95(2):437-445.
17. Ashton JC, Rahman RMA, et al Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci Lett 2007; 412(2):114-117.
18. Benito C, Romero JP, Tolon RM, et al. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 2007; 27(9):2396-2402.
19. Lange JH, Kruse CG. Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. Drug Discov Today 2005; 10(10):693-702.
20. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3(9):771-784.
21. Guzman M, Sanchez C, Galve-Roperh I. Cannabinoids and cell fate. Pharmacol Ther 2002; 95(2):175-184.
22. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nature Rev 2005; 5:400-411.
23. Fernandez-Lopez D, Martinez-Orgado J, Nunez E, et al. Characterization of the Neuroprotective Effect of the Cannabinoid Agonist WIN-55212 in an in vitro Model of Hypoxic-Ischemic Brain Damage in Newborn Rats. Pediatr Res 2006; 60(2):169-173.
24. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005; 310(5746):329-332.
25. Eljaschewitsch E, Witting A, Mawrin C, et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 2006; 49(1):67-79.
26. Gong JP, Onaivi ES, Ishiguro H, et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 2006; 1071(1):10-23.
27. Golech SA, McCarron RM, Chen Y, et al. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res 2004; 132(1):87-92.
28. Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001; 60(1):155-163.
29. Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 2002; 42(11 Suppl):11S-19S.
30. Fride E, Foox A, Rosenberg E, et al. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice:; evidence for a "CB3" receptor. Eur J Pharmacol 2003; 461:27-34.
31. Baker D, Pryce G, Davies WL, Hiley CR. in silico Patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 2006; 27(1):1-4.
32. Fowler CJ. Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents. Non-psychoactive cannabinoids, 'entourage' compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid pyschotropic effects. Brain Res Brain Res Rev 2003; 41(1):26-43.
33. Wilson RI, Nicoll RA. Endocannabinoid signalling in the brain. Science 2002; 296:678-682.
34. Lambert DM, Fowler CJ. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem 2005; 48(16):5059-5087.
35. Chen Y, Swanson RA. Astrocytres and brain injury. J Cereb Blood Flow Metab 2003; 23:137-149.
36. Ortega-Gutierrez S, Molina-Holgado E, Guaza C. Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte culture. Glia 2005; 52(2):163-168.
37. Fernandez-Ruiz J, Berrendero F, Hernandez ML, Ramos JA. The endogenous cannabinoid system and brain development. Trends Neurosci 2000; 23:14-20.
38. Fernandez-Ruiz J, Gomez M, Hernandez M, De Miguel R, Ramos JA. Cannabinoids and gene expression during brain development. Neurotox Res 2004; 6:1-14.
39. Fride E. The endocannabinoid-CB1 receptor systeme in pre- and postnatal life. Eur J Pharmacol 2004; 500:289-297.
40. Romero J, Garcia-Palomero E, Berrendero F, et al. Atypical location of cannabinoid receptors in white matter areas during rat brain development. Synapse 1997; 26(3):317-323.
41. Aguado T, Monory K, Palazuelos J, et al. The endocannabinoid system drives neural progenitor proliferation. FASEB J 2005; 19(12):1704-1706.
42. Jiang W, Zhang Y, Xiao L, et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 2005; 115(11):3104-3116.
43. Molina-Holgado E, Vela JM, Arevalo-Martin A, et al. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 2002; 22(22):9742-9753.
44. Arevalo-Martin A, Vela JM, Molina-Holgado E, Borrell J, Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 2003; 23(7):2511-2516.
45. Abrahamov A, Abrahamov A, Mechoulam R. An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci 1995; 56(23-24):2097-2102.
46. Volpe JJ. Perinatal brain injury: from pathogenesis to neuroprotection. Ment Retard Dev Disabil Res Rev 2001; 7(1):56-64.
47. Ferriero DM. Neonatal brain injury. N Engl J Med 2004; 351(19):1985-1995.
48. du Plessis AJ, Volpe JJ. Perinatal brain injury in the preterm and term newborn. Curr Opin Neurol 2002; 15(2):151-157.
49. Martinez-Orgado J, Fernandez-Lopez D, Moro MA, Lizasoain I. Nitric Oxide synthase as a target for the prevention of hypoxic-ischemic newborn brain damage. Curr Enzym Inhib 2006; 2:219-229.
50. Saugstad O. Role of xanthine oxidase and its inhibitor in hypoxia: reoxygenation injury. Pediatrics 1996; 98:103-107.
51. Warner DS, Shang H, Batinic-Haberle I. Oxidants, antioxidents and the ischemic brain. J Exp Biol 2004; 207:3221-3231.
52. Johnston MV. Excitotoxicity in neonatal hypoxia. Ment Retard Dev Disabil Res Rev 2001; 7(4):229-234.
53. Berger R, Garnier Y. Perinatal brain injury. J Perinat Med 2000; 28:261-285.
54. Fernandez-Lopez D, Martinez-Orgado J, Casanova I, et al. Immature rat brain slices exposed to oxygen-glucose deprivation as an in vitro model of neonatal hypoxic-ischemic encephalopathy. J Neurosci Methods 2005; 145(1-2):205-212.
55. Allan SM, Rothwell NJ. Cytokines and acute neurodegeneration. Nat Rev Neurosci 2001; 2:734-740.
56. Takuma K, Baba A, Matsuda T. Astrocyte apoptosis: implications for neuroprotection. Prog Neurobiol 2004; 72:111-127.
57. Mishra OP, Fritz KI, Delivoria-Papadopoulos M. NMDA receptor and neonatal hypoxic-ischemic brain injury. Ment Retard Dev Disabil Res Rev 2001; 7:249-253.
58. Vexler ZS, Ferriero DM. Molecular and biochemical mechanisms of perinatal brain injury. Semin Neonatal 2001; 6(2):99-108.
59. Roth KA, D'Sa C. Apoptosis and brain development. Ment Retard Dev Disabil Res Rev 2001; 7:261-266.
60. Martinez-Orgado J, Gonzalez R, Alonso MJ, Rodriguez-Martinez MA, Sanchez-Ferrer CF, Marin J. Endothelial factors and autoregulation during pressure changes in isolated newborn piglet cerebral arteries. Pediatr Res 1998; 44(2):161-167.
61. Yang Z, Covey MV, Bitel CL, Ni L, Jonakait GM, Levison SW. Sustained neocortical neurogenesis after neonatal hypoxic/ischemic injury. Ann Neurol 2007; 61(3):199-208.
62. Ong J, Plane JM, Parent JM, Silverstein FS. Hypoxic-ischemic injury stimalates subventricular zone proliferation and neurogenesis in the neonatal rat. Pediatr Res 2005; 58(3):600-606.
63. Zaidi AU, Bessert DA, Ong JE, et al. New oligodendrocytes are generated after neonatal hypoxic-ischemic brain injury in rodents. Glia 2004; 46(4):380-390.
64. Groenendaal F, De Vries L. Selection of babies for intervention after birth asphyxia. Semin Neonatol 2000; 5:17-32.
65. Edwards AD, Azznpardi DV. Therapeutic hypothermia following perinatal asphyxia. Arch Dis Child Fetal Neonatal Ed 2006; 91(2):F127-F131.
66. Higgins RD, Raju TN, Perlman J, et al. Hypothermia and perinatal asphyxia: executive summary of the National Institute of Child Health and Human Development workshop. J Pediatr 2006; 148(2):170-175.
67. Gluckman PD, Wyatt JS, Azzopardi D, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet 2005; 365(9460):663-670.
68. Vannucci RC, Perlman JM. Interventions for perinatal hypoxic-ischemic encephalopathy. Pediatrics 1997; 100(6):1004-1014.
69. Mechoulam R, Panikashvili D, Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol Med 2002; 8(2):58-61.
70. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 2006; 105(1-2):1-25.
71. Maresz K, Pryce G, Ponomarev ED, et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB(1) on neurons and CB(2) on autoreactive T cells. Nat Med 2007; 13(4):492-497.
72. Zhuang SY, Bridges D, Grigorenko EV, et al. Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores. Neuropharmacology 2005; 48:1086-1096.
73. Hajos N, Ledent C. Freund TF. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 2001; 106(1):1-4.
74. Breivogel CS, Walker JM, Huang SM, Roy MB, Childers SR. Cannabinoid signaling in rat cerebellar granule cells: G-protein activation, inhibition of glutamate release and endogenous cannabinoids. Neuropharmacology 2004; 47(1):81-91.
75. Hamrick SE, Ferriero DM. The injury response in the term newborn brain: can we neuroprotect? Curr Opin Neurol 2003; 16(2):147-154.
76. Kim SH, Won SJ, Mao XO, Jin K, Greenberg DA. Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity. Mol Pharmcol 2006; 69:691-696.
77. Waksman Y, Olson JM, Carlisle SJ, Cabral GA. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J Pharmacol Exp Ther 1999; 288(3):1357-1366.
78. Molina-Holgado F, Pinteaux E, Moore JD, et al. Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci 2003; 23(16):6470-6474.
79. Juttler E, Potrovita I, Tarabin V, et al. The cannabinoid dexanabinol is an inhibitor of the nuclear factor-kappa B (NF-kappa B). Neuropharmacology 2004; 47(4):580-592.
80. Croxford JL, Yamamura T. Cannabinoids and the immune system: potential for die treatment of inflammatory diseases? J Neuroimmunol 2005; 166(1-2): 3-18.
81. Klein TW, Lane B, Newton CA, Friedman H. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 2000; 225(1):1-8.
82. Croxford JL, Miller SD. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. J Clin Invest 2003; 111(8):1231-1240.
83. Marsicano G, Goodenough S, Monory K, et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003; 302(5642):84-88.
84. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 1998; 95(14):8268-8273.
85. Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 2002; 80(3):448-456.
86. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernandez-Ruiz J. Cannabinoids provide neuroprotection in experimental models of Parkinson's disease: involvement of their antioxidant properties and/or glial cell-mediated effects. Neurobiol Dis. In press.
87. Pertwee RG, Nash K, Trayhum P. Evidence that the hypothermic response of mice to delta-9-tetrahydrocannabinol is not mediated by changes in thermogenesis in brown adipose tissue. Can J Physiol Pharmacol 1991; 69(6):767-770.
88. Leker RR, Gai N, Mechoulam R, Ovadia H. Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210. Stroke 2003; 34(8):2000-2006.
89. Ovadia H, Wohlman A, Machoulam R, Weidenfeld J. Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens. Neuropharmacology 1995; 34(2):175-180.
90. Hillard CJ. Endocannabinoids and vascular function. J Pharmacol Exp Ther 2000; 294(1):27-32.
91. Aguado T, Palazuelos J, Monory K, et al. The endocannabinoid system promotes astroglial differentiation by acting on neural progenitor cells. J Neurosci 2006; 26(5):1551-1561.
92. Docagne F, Muñetón V, Clemente D, et al. Excitotoxicity in a chronic model of multiple sclerosis: neuroprotective effect of cannabinoids through CB1 and CB2 receptor activation. Mol Cell Neurosci 2007; doi:10.1016/j.mcn.2006.12.005(34):551-561.
93. Gomez del Pulgar T, De Ceballos ML, Guzman M, Velasco G. Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylimositol 3-kinase/protein kinase B pathway. J Biol Chem 2002; 277(39):36527-36533.
94. Hansen HS, Moesgaard B, Petersen G, Hansen HH. Putative neuroprotective actions of N-acyl-ethanolamines. Pharmacol Ther 2002; 95:119-126.
95. Nagayama T, Sinor AD, Simon RP, et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999; 19(8):2987-2995.
96. Sinor AD, Irvin SM, Greenberg DA. Endicannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci Lett 2000; 278:157-160.
97. Grundy RI, Rabuffetti M, Beltramo M. Cannabinoids and neuroprotection. Mol Neurobiol 2001; 24(1-3):29-51.
98. Braida D, Pegorini S, Arcidiacono MV, Consalez GG, Croci L, Sala M. Post-ischemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils. Neurosci Lett 2003; 346(1-2):61-64.
99. Bonfils PK, Reith J, Hasseldam H, Johansen FF. Estimation of the hypothermic component in neuroprotection provided by cannabinoids following cerebral ischemia. Neurochem Int 2006; 49(5):508-518.
100. Belayev L, Busto R, Zhao W, Ginsberg MD. HU-211, a novel noncompetitive N-methyl-D-aspartate antagonist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat. Stroke 1995; 26(12):2313-2319.
101. Van der Stelt M, Veldhuis WB, Bar PR, Veldink GA, Vliegenthart JF, Nicolay K. Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotxicity. J Neurosci 2001; 21(17):6475-6479.
102. Martinez-Orgado J, Fernandez-Frutos B, Gonzalez R, et al. Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia. Brain Res Mol Brain Res 2003; 114(2):132-139.
103. Parmentier-Batteur S, Jim K, Mao XO, Xie L, Greenberg DA. Increased sverity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci 2002; 22:9771-9775.
104. Van der Stelt M, Veldhuis WB, van Haaften GW, et al. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J Neurosci 2001; 21(22):8765-8771.
105. Zygmunt PM, Petersson J, Andersson DA, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999; 400(6743):452-457.
106. Rice JE, Vannucci RC, Brierley JB. The influence of immaturity on hypoxicischemic brain damage in the rat. Ann Neurol 1981; 9:131-141.
107. Fernandez-Lopez D, Pazos MR, Tolon RM, et al. The cannabinoid agonist WIN55212 reduces brain damage in an in vivo model of hypoxic-ischemic encephalopathy in newborn rats. Pediatr Res 2007; (in press).
108. Volpe JJ. Hypoxic-ischemic encephalopathy: clinical aspects. In: Volpe JJ, editor. Neurology of the Newborn. Philadelphia: WB Saunders Co, 2001: 331-394.
109. Makriyannis A, Deng H. US20077173027 (2007).
110. Martin DR, Richmond VA, Razdan RK, US20077179800 (2007).
111. Zhang M, Martin BR, Adler MW, Razdan RK, Jallo JI, Tuma RF. Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J Cereb Blood Flow Metab 2007; doi:10.1038/ sj.jcbfm.9600447.
112. Garzon A, Fink G. EP1299374B1 (2006).
113. Hansen HH, Schmid PC, Bittigau P, et al. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration, J Neurochem 2001; 78:1415-1427.
114. Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci 2003; 23(21):7767-7775.
115. Jin KL, Mao XO, Goldsmith PC, Greenberg DA, CB1 cannabinoid receptor induction in experimental stroke. Ann Neurol 2000; 48:257-261.
116. Panikashvili D, Simeonidou C, Ben Shabat S, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001; 413(6855):527-531.
117. Van der Stelt M, Veldhuis WB, Maccarrone M, et al. Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 2002; 26(2-3): 317-346.
118. Karanian DA, Brown QB, Makriyannis A, Kosten TA, Bahr BA. Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J Neurosci 2005; 25(34):7813-7820.
119. Cabranes A, Venderova K, de Lago E, et al. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol Dis 2005; 20(2):207-217.
120. de Lago E. Fernandez-Ruiz J, Ortega-Gutierrez S, Viso A, Lopez-Rodriguez ML, Ramos JA. UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. Eur J Pharmacol 2002; 449(1-2):99-103.
121. Shohami E, Novikov M, Mechoulam R. A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat. J Neurotrauma 1993; 10(2):109-119.
122. Knoller N, Levi L, Shoshan I, et al. Dexanabinol (HU-211) in the treatment of severe closed head injury: A randomized, placebo-controlled, phase II clinical trial*. Crit Care Med 2002; 30:548-554.
123. Barnes MP. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother 2006; 7(5):607-615.
124. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65(6):812-819.
125. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006; 66(2):234-246.
126. Stella N. Cannabis Sativa: getting closer to separating the medicinal properties from the drug of abuse. J Neuroimmunol 2005; 166(1-2):1-2.
127. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005; 76(12):1664-1669.
128. Iskedjian M, Bereza B, Gordon A, Piwko C, Emarson TR. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 2007; 23(1):17-24.
129. Beaulieu P. Cannabinoids for postoperative pain. Anesthesiology 2007; 106(2):397-398.
130. Hall W, Christie M, Currow D. Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol 2005; 6(1):35-42.
131. Sutton IR, Daeninck P. Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancer-related pain. J Support Oncol 2006; 4(10):531-535.
132. Smith PF. GW-1000. GW Pharmaceuticals. Curr Opin Investig Drugs 2004; 5(7):748-754.
133. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford) 2006; 45(1):50-52.
134. Perez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barc) 2006; 42(8):495-503.
135. GWPharma Ltd. GB0601013A0 (2006).